234 related articles for article (PubMed ID: 21354800)
1. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
3. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
Zhang S; Yang X; Coburn RA; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
[TBL] [Abstract][Full Text] [Related]
4. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Marighetti F; Steggemann K; Hanl M; Wiese M
ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
Nicolle E; Boccard J; Guilet D; Dijoux-Franca MG; Zelefac F; Macalou S; Grosselin J; Schmidt J; Carrupt PA; Di Pietro A; Boumendjel A
Eur J Pharm Sci; 2009 Aug; 38(1):39-46. PubMed ID: 19501160
[TBL] [Abstract][Full Text] [Related]
7. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
8. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Pick A; Müller H; Wiese M
Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
[TBL] [Abstract][Full Text] [Related]
11. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
13. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
14. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
15. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Erić S; Kalinić M; Ilić K; Zloh M
SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
17. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibitors of the breast cancer resistance protein (BCRP).
Pick A; Klinkhammer W; Wiese M
ChemMedChem; 2010 Sep; 5(9):1498-505. PubMed ID: 20632361
[TBL] [Abstract][Full Text] [Related]
19. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
20. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
Fleisher B; Unum J; Shao J; An G
J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
